The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patients

NCT03228368 · clinicaltrials.gov ↗

UNKNOWN

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Atezolizumab (MPDL3280A)

Sponsor

First Affiliated Hospital of Zhejiang University

Collaborators

[object Object]
[object Object]